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bined the findings from all three genomes 
to check sequence or patent overlap and 
redundancy.
Results show that only 24% (2,367 out of 
9,838), 15% (1,190 out of 7,836) and 24% 
(2,595 out of 10,634) of the earlier accounted 
for as maize, rice and soybean referenced 
sequences, respectively, were actually used in 
plant-related inventions. These correspond 
to 846 maize-related patents, 493 rice-related 
patents and 638 soybean-related patents—or 
1,633 granted patents in total, as we found 
some overlapping patents across the three 
data sets. The level of overlap among refer-
enced sequences was 9% and redundancy was 
more than 30%, and only 10% of sequences 
comprised more than 50 base pairs.
According to the US classification codes, in 
the hand-edited collection, 65% of inventions 
were related to the processes of introducing or 
rearranging a nucleic acid molecule into a plant 
cell or part, either as such or to develop a trans-
genic plant or plant part; 48% were related to a 
plant per se (including a higher plant), seedling 
or plant seed or part; 45% were related to the 
use of vectors for the introduction of exogenous 
nucleic acid molecules in host cells; and 33% 
were related to the transformed plant cell or cell 
line or to plant proteins used as compounds.
Claim analysis, on the other hand, revealed 
clearer patterns of sequence use. Although 
sequence use was broadly similar in plant- 
and human-related inventions—on the basis 
of the categories identified in our human 
genome study8—in plant-related inventions, 
such use was more intertwined within a single 
patent document. For example, in US patent 
8,692,076 (available at https://www.lens.org/
lens/patent/US_8692076_B2), the sequence 
identified as SEQ ID No: 1 was mentioned 
in claim 1 as part of a larger sequence and so 
would have been categorized as a “Subpart” in 
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The restructuring of the crop agriculture industry over the past two decades has enabled patent holders to exclude, 
prevent and deter others from using certain research tools and delay or block further follow-on inventions.
The raging legal debates on the patent eli-gibility of genetic sequences extend from 
Europe, where in 2010 the European Court 
of Justice in Monsanto Technology LLC v. 
Cefetra BV held that protection for a pat-
ent claiming a DNA sequence is limited by 
a “functionality” requirement as disclosed 
in the patent document1, to the United 
States, where from 2012 to 2013, the US 
Supreme Court in Association for Molecular 
Pathology v. Myriad Genetics, Inc.2 and Mayo 
Collaborative Services v. Prometheus Labs, 
Inc.3 upheld a shift in the broad scope of 
patentability of genetic sequences. In fact, 
owing to additional social and moral con-
cerns over human or plant gene patents, 
governments of countries such as Brazil and 
China have also tried, either through court 
decisions and/or enacted policies, to shape 
their own standards within the international 
legal framework and their ability to restrict 
the patentability of subject matter—be it in 
medicine or industrial agriculture4,5.
For example, Brazil allows the patenting of 
methods to transform plants and expression 
vectors containing heterologous sequences, 
but it does not allow the patenting of biologi-
cal sequences isolated from plants or any parts 
of plants and plant varieties6. China allows 
the patenting of isolated sequences, modified 
sequences and transformed plant cells, but 
carves out exclusions to make all or part of 
plants and plant varieties unpatentable7.
Thus, considering how divergent and 
complex the spectrum of interests in gene 
 patenting is becoming and how limited is our 
understanding of the practices across various 
economies, we have designed and developed 
a dynamic platform, the patent sequence 
(PatSeq) toolkit, to render biological patents 
and their disclosed genetic sequences more 
publicly accessible and their contextual navi-
gation more evidence based8.
We recently reported9 on the mapping of 
patent-disclosed sequences onto three crop 
genomes (maize, rice and soybean), the analysis 
of overlapped sequences among plant and 
human genomes, and on the recently adopted 
changes to the scope of patentability introduced 
by the United State Patent and Trade Office 
(USPTO). Here, we hand edit each of the three 
plant genome patent sequence maps to identify 
sequences referenced in the claims of granted 
patents and analyze their corresponding patent 
ownership within the context of other plant 
intellectual property (IP) rights. We conclude 
by discussing the impact of the current per-
ceptions of ownership on the industry and the 
public interests.
Referenced sequences that may be 
related to plant inventions
The task of determining which of the mapped 
sequences were referenced in plant-related 
inventions was challenging, as we could 
not rely on the original sequence source to 
identify relevant patent sequences. In addi-
tion, and unfortunately, the majority of the 
referenced sequences in granted claims had 
non-plant origins or were unknown, unspeci-
fied or artificial. We initially used US clas-
sification codes to screen the corresponding 
patents and eliminate non-plant patents, then 
hand edited the data and analyzed broadly 
the claims to assemble inventions that can be 
related to plants or cover basic research topics 
that may be applied to plants. We then com-
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the use of sequence as ‘isolated’ or in a vector; 
the use of the vector; and the use of geneti-
cally modified host cells, host plant(s), seeds, 
progenies and methods to produce, detect 
and use such sequences.  Method claims, be 
they to regulate plant gene expression, target 
genome changes or improve or manage crop 
yield by genetic engineering methods, were 
very common, as were claims covering basic 
core research technologies. To enable further 
technology landscaping of the data, we pro-
vide the unedited raw sequences in PatSeq 
Explorer (https://www.lens.org/lens/bio/
patseqexplorer) and are happy to collaborate 
on the further analyses of the hand-edited 
 collection of plant related inventions.
Ownership of plant-related gene patents
To disambiguate applicant and owner names 
in the hand-edited collection, we consulted 
the publicly available assignment data from 
the USPTO (ref. 10), curated and cleaned 
applicant data from the European Patent 
Office’s DOCDB database and further 
explored each company, including its name 
changes, acquisitions, mergers and joint 
ventures, through press releases, company 
websites and other publicly available data11. 
The cumbersome and incomplete process 
underlines an important need for a globally 
harmonized data set with persistent identi-
fiers for patent ownership, including corpo-
rate relationships that illuminate the ultimate 
owner of patents.
The biggest lacuna in this analysis—the 
‘elephant in the room’ of all patent analy-
ses—is the absence in the public record of 
who owns the rights to a patent. Licensing 
information is rarely made public but would 
completely change the understanding of the 
state of competition and trust formation and 
the effectiveness of policy instruments, invest-
ment tools and public science and technology 
expenditure priorities. In principle, virtually 
all analyses of patent control are confounded 
and could be misleading or completely incor-
rect in the absence of comprehensive licens-
ing information. If this is not made statutorily 
available, global innovation policy—in gene 
patenting and in all contentious and impor-
tant domains of innovations—will be based 
on surmise and on the easy data, not the right 
data.
Nonetheless, with the data that can readily 
be gleaned publicly, our analysis of mapped 
and referenced patent sequences across the 
three crop genomes revealed DuPont and its 
affiliates as the holder of the largest collection 
our human genome study. The same sequence 
is mentioned as the target of a detection 
assay in claim 3 and so would have been cat-
egorized as a “Target” with respect to that 
claim. SEQ ID No: 1 then appears in claims 
4, 7 and 12 as part of a genetically modified 
soybean plant or seed and so would have 
been categorized as “Alter phenotype” with 
respect to those claims. In other words, the 
same sequence would have been categorized 
three different ways for this patent, and this 
does not include claims that encompass the 
sequence without explicitly mentioning it, 
such as for example claim 8. Therefore, unlike 
in humans, granted claims covering plant-
related genes or gene fragments comprised 
0
100
200
Maize Rice Soybean
400
500
600
700
800
900
1,000
M
on
sa
nt
o
Du
Po
nt
US
 u
niv
er
sit
y
US
 re
se
ar
ch
 in
sti
tu
te
Ba
ye
r
BA
SF
No
va
rti
s
Sy
ng
en
ta
Lim
ag
ra
in
US
 g
ov
er
nm
en
t
M
on
sa
nt
o
Du
Po
nt
US
 u
niv
er
sit
y
US
 re
se
ar
ch
 in
sti
tu
te
Ba
ye
r
BA
SF
No
va
rti
s
Sy
ng
en
ta
Lim
ag
ra
in
US
 g
ov
er
nm
en
t
M
on
sa
nt
o
Du
Po
nt
US
 u
niv
er
sit
y
US
 re
se
ar
ch
 in
sti
tu
te
Ba
ye
r
BA
SF
No
va
rti
s
Sy
ng
en
ta
Lim
ag
ra
in
US
 g
ov
er
nm
en
t
Sequences-GC
Granted patents
S
eq
ue
nc
e 
or
 p
at
en
t 
nu
m
b
er
 (p
la
nt
 r
el
at
ed
)
Figure 1  Holdings of granted patents and their referenced sequences in the claims (GC) of the 
hand-edited plant-related collection, based on the edited applicant and owner data. Only the top 10 
applicants are shown.
Figure 2  Contribution of public and private sectors to maize, rice and soybean gene patenting activities from 1993–2014. Number of granted patents (a) or 
referenced sequences in granted claims (b) in the hand-edited plant-related collection, according to the mapping of patent sequences onto maize, rice and 
soybean genomes combined and their reference in granted claims.
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of gene patents. It holds more gene patents 
than Monsanto or the rest of the US indus-
try—including small and medium biotech 
companies and governmental research insti-
tutes and  universities—put together (Fig. 1).
We cannot ascertain that these results 
represent actual practices, as we have not 
accounted for the cross-licensing agreements 
that take place between various IP owners. 
The results also suggest that the public sector, 
which includes universities, government and 
research institutes, is active in plant-related 
gene patenting. So, to draw a larger perspec-
tive on its contribution, we grouped our data 
on the basis of the affiliation of the applicant 
or owner—either to the public or the private 
sector—and plotted it against publication 
year (1993–2014). Similar grouping was also 
performed using the referenced sequence 
data.
We found that the public sector’s activity 
in plant gene patenting has been signifi-
cant throughout the past 22 years. At the 
early stage of biotechnology and biological 
research on these genomes, the public sec-
tor’s contribution was 40–50% by 2000. Since 
then it has varied, between 12.5% (in 2005) 
and 27.9% (in 2014), with an average of 25% 
annual contribution, on the basis of the pat-
ent holdings in the hand-edited collection 
(Fig. 2a). These findings are similar to what 
was reported in 2003 (ref. 12). However, 
as our results cover only three major agri-
cultural crops and extend from the 1990s 
to 2014, they suggest a gradually widening 
gap in the ownership of plant gene patents 
between the private and public sectors. Again, 
this conclusion is subject to the caveats that 
assignments of public IP to private hands—or 
indeed exclusive licensing—are not typically 
a matter of public record.
Upon using the referenced sequence hold-
ings as a proxy to public sector’s contribu-
tion to the inventions, we found that in the 
early stages of biotechnology and biological 
research, the public sector was less active 
than the private sector in capturing or refer-
encing sequences in patent claims until 2005, 
when it started to reference a large number of 
sequences in patent claims (Fig. 2b), imply-
ing the emergence of a convergent business 
model between the sectors in the past decade.
Here also, we limited our analysis to plant-
related gene patents, but to provide a broader 
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Figure 3  PVP certificates issued for three major crop varieties, 1990–2014. Number of certificates issued for maize (a), rice (b) and soybean (c) varieties in 
the United States, based on USDA data18.
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varieties can be protected by a specific plant 
patent under the Plant Patent Act of 1930 
for asexually reproducible plants; by a plant 
variety protection (PVP) certificate under 
the Plant Variety Protection Act of 1970 for 
sexually reproducible plants or tuber-propa-
gated plant varieties; or, since 1985, by utility 
patents16.
Because several types of protection can be 
granted at the same time—for example, either 
a plant patent or a PVP certificate with a util-
ity patent—and exclusive rights extend for 
20 years, any IP right holder on any of the 
crops can in principle benefit not only by 
enforcing their IP rights but also by holding 
off competition in the market and potentially 
delaying innovation on certain technologies, 
especially when the granted rights are under 
utility patents17. Utility patents have a broader 
scope, including protection on the plant itself, 
its diverse uses, its progenies and the method 
used to produce it, and they have an impact 
on follow-on innovations.
To examine utility patent holdings and PVP 
certificates issued on maize, rice and soybean, 
we requested and received records on plant 
variety certificates issued on each of the three 
crops from the United States Department of 
Agriculture18 and created utility patent col-
lections in the Lens, using US classification 
codes for maize (800/320.1), rice (800/320.2) 
and soybean (800/312). In addition, for each 
data set we hand-edited and disambiguated 
the names of applicants or owners and plotted 
patent and certificate holdings on the basis 
of the date issued (for certificates) or the fil-
ing year (for utility patents). We found that 
between 31 August 1990 and 19 September 
2014, a total of 1,963; 111; and 1,991 PVP cer-
tificates were issued on maize, rice and soy-
bean varieties, respectively, and 3,566; 409; 
and 2,967 utility patents were granted on each 
crop, respectively. 
Plotting PVP and patent holdings over 
the past 25 years confirms that DuPont and 
Monsanto, including their published subsid-
iaries and acquisitions, have held a dominant 
position over maize and soybean genome IP 
over time, followed by Syngenta and BASF 
(Figs. 3 and 4). The data also show that the 
major IP holders were involved in IP acquisi-
tions as early as 1990 and that although the 
number of holdings was increasing, a gap 
was forming between these entities and other 
applicants and owners (Figs. 3a,c and 4a,c) in 
that industry, confirming a gradual consolida-
tion of IP in a few key players. By 2008–2010, 
small or individual owners appear to have 
been almost nonexistent.
In rice, trends were slightly different. With 
fewer holdings in both PVP and utility patents 
view of current maize, rice and soybean IP 
practices, we extended the analysis to include 
those on utility patents that target genomes 
rather than genes and other IP data such as 
that on plant variety protection certificates. 
Currently, various legal regimes are available 
to protect plants13, the industry is heavily 
concentrated14 and old gene technologies 
are evolving into genome-based modifica-
tion technologies15, particularly in the United 
States, where applicants can double protect a 
plant genome.
Genome IP practices in the  
United States
Uniquely in the United States, plants and their 
products can be protected by patents and by 
other IP mechanisms at the same time. Plant 
Figure 4  Utility patents issued from 1990 to 2014. Utility patents issued on maize (a), rice (b) and 
soybean (c) plants, based on searches for US classification codes 800/320.1 (maize), 800/320.2 (rice) 
and 800/312 (soybean).
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it would not be enough. The power of a patent 
lies in the rights to exclude, or not be excluded, 
and these rights can be transferred separately 
from ownership in the form of a license. 
A critical policy imperative should mandate 
public disclosure and recordation of licens-
ing status of patents derived from such public 
research, or conducted by public institutions 
under contract. Only then can we sensibly 
assess the degree of compliance with public 
goals, or capture by private interests, and take 
evidence-based steps to improve the desired 
outcomes. 
As public investment in crop agriculture con-
tinues to stagnate23, the public innovation space 
risks capture by private interests, and moving 
away from modest market and margins, or 
innovations with many but diffuse beneficia-
ries, such as those promoting environmental 
benefit, focusing rather on financially valuable 
inventions with high-value capture potential. 
This outcome would be of questionable desir-
ability for goals of diversification and resilience 
and could affect many economies, environ-
ments and communities.
Only through dramatic improvements in 
transparency—of patent meaning, of patent 
ownership, of license status and of placement 
of patent rights in the context of innovation 
knowledge—can the full potential of science 
and technology in agricultural innovation be 
reached, with the broadest canvas of ideas, par-
ticipants and public support.
Note: Any Supplementary Information and Source Data 
files are available in the online version of the paper 
(doi:10.1038/nbt.3393). 
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than for maize or soybean, rice showed a more 
diverse set of applicants. It seems that from 2003 
onward, research institutes and farmer coopera-
tives have been more engaged in acquiring PVP 
certificates than have DuPont or Monsanto, 
for example (Fig. 3b). However, DuPont has 
remained active in acquiring utility patents on 
rice since 1996, as far as the public records show 
(Fig. 4b).
Complementing these results with those 
obtained from ownership analysis of the hand-
edited plant-related collection re-asserts the 
dominant role of DuPont and its affiliates in 
plant-related IP portfolio globally, followed by 
the US industry, which includes small biotech 
companies, governmental research institutes 
and universities, and then by Monsanto and its 
affiliates.
These results may or may not represent 
actual practices; as discussed above, patent 
owners are not legally required to disclose reas-
signment or licensing data to the patent office. 
The public can see only the information that a 
patent owner chooses to provide. For example, 
a large biotech could license all or part of its 
patent portfolio to another large biotech, which 
could in turn sublicense it to a smaller company. 
A young entrepreneur interested in that collec-
tion of patents could spend huge sums on law-
yer’s fees for investigating the true ownership of 
each patent or developing a freedom-to-operate 
analysis before even beginning to make a prod-
uct for market. 
Global trends of gene and genome  
IP practices
Plant gene practices in Europe may vary slightly, 
as Europe’s IP laws are different. Under Articles 
1–11 of Directive 98/44/EC of the European 
Parliament and of the Council of 6 July 1998 
on the legal protection of biotechnological 
inventions, IP rights on plants are permissible 
only when the invention covers plants in gen-
eral and regardless of the kind of plant variety, 
so plant varieties as such are not a patentable 
subject matter19. Diverse national policies have 
been adopted worldwide to regulate IP rights 
on plants and plant varieties (Supplementary 
Table 1), especially in jurisdictions where plants 
are part of the country’s culture and basic food; 
for example, in Asia specific provisions were 
incorporated into national IP laws to render 
rice a nonpatentable subject matter20.
Moreover, under Article 27.3 of the interna-
tional Agreement on Trade-Related Aspects 
of Intellectual Property Rights (TRIPS), each 
member government has the authority to pro-
vide its own sui generis IP systems to protect 
plants or plant varieties as an alternative to util-
ity patents and carve exclusions21. Plant variety 
protection, which is based on the International 
Union for the Protection of New Varieties of 
Plants (UPOV) guidelines, is a valid alterna-
tive used by many governments. Under UPOV, 
members may, and in some cases have intro-
duced exclusions such as “[i] exclusion of plants 
from patent protection; [ii] exclusion of plant 
varieties from patent protection; [iii] exclusions 
of both plants and plant varieties from patent 
protection; [iv] allowing the patentability of 
plants, and [v] excluding or allowing the pat-
entability of essential biological process for the 
production of plants.”20 Further discussions 
on such flexibilities can be found in the docu-
ment prepared by the Secretariat of the World 
Intellectual Property Organization (WIPO) and 
published at the 13th session of the Committee 
on Development and Intellectual Property 
(CDIP).
Conclusions
The restructuring of the crop agriculture indus-
try in the 1980s and 1990s and the strategic use 
of patent rights enabled some large-scale patent 
holders to exclude or deter others from using 
critical research tools and materials14,22. This 
legal and expected use—delaying or otherwise 
limiting competitive products or follow-on 
inventions—allowed a few corporations to 
influence or control much of global agricultural 
innovation, a situation that many find disquiet-
ing, and which may lie at the heart of the ongo-
ing resistance to new agricultural technologies.
Efforts to improve the system to increase fair-
ness, relevance, diversity of participation and 
trust must be based on sufficient transparency 
to ensure evidence-based and inclusive policy 
and practice.
For instance, plant-related gene patents 
were fewer and harder to identify through 
patent sequence analyses than human-related 
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